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Mast cells are central players in immune surveillance and activation, positioned at the host–
environment interface. Understanding the signaling events controlling mast cell function,
especially those that maintain host homeostasis, is an important and still less understood
area of mast cell-mediated disease.With respect to allergic disease, it is well established
that IgE and its high afﬁnity receptor FcεRI are major mediators of mast cell activation.
However, IgG-mediated signals can also modulate mast cell activities. Signals elicited by
IgG binding to its cognate receptors (FcγR) are the basis for autoimmune disorders such
as lupus and rheumatoid arthritis. Using knowledge of IgE-mediated mast cell signaling,
recent work has begun to illuminate potential overlap between FcεRI and FcγR signal
transduction. Herein we review the importance of Src family kinases in FcεRI and FcγR
signaling, the role of the transcription factor STAT5, and impingement of the regulatory
cytokines IL-4, IL-10, andTGFβ1 upon this network.
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INTRODUCTION
Mast cells are key agents in the direction of inﬂammatory processes
throughout most tissues, especially at the mucosal interface.
Immediately identiﬁable consequences of mast cell activity are the
symptoms of atopic disease: itching, sneezing, and allergic asthma.
Mast cells enact these processes through degranulation of stored
histamine, various proteases, and the secretion of prostaglandins
and leukotrienes. Mast cells further affect inﬂammatory responses
by the later (hours) de novo production and secretion of a plethora
of cytokines, chemokines, and growth factors, including TNF-α,
GM-CSF, IL-4, -6, -13,MIP-1α,MCP-1, andVEGF. Thus mast cells
also act as effectors of other cellular responses, e.g.,maintenance of
IgE production, and the activities of regulatory T cells (Treg) and
myeloid derived suppressor cells (MDSC; Gauchat et al., 1993;
Frandji et al., 1996; Pawankar et al., 1997; Lu et al., 2006; Forward
et al., 2009; Kambayashi et al., 2009; Piconese et al., 2009; Yang
et al., 2010b). Notwithstanding their very important and deeply
studied roles in atopy and parasite infections, mast cells are now
implicated in the inﬂammatory responses associated with autoim-
mune disease, atherosclerosis, and resistance to bacterial infection
(Levi-Schaffer et al., 1991; Malaviya et al., 1996; Secor et al., 2000;
Hara et al., 2002; Lee et al., 2002;McLachlan et al., 2003). Thismul-
tifunctional role in the immune response makes mast cell biology
a critical area of research that could greatly change the treatment
of inﬂammatory diseases.
Investigation of signals proximal to the high afﬁnity IgE recep-
tor, FcεRI, has been a topic of great interest due to the importance
of IgE in allergic pathologies. Central points from these obser-
vations are that Src family kinases Lyn and Fyn are critical to
IgE-mediated mast cell activation, and that the signal transducer
and activator of transcription (STAT) 5 transcription factor medi-
ates mast cell vitality and function, particularly in the late phase
of cytokine production. Knowledge gained from FcεRI signaling
could prove valuable in the setting of IgG-mediated inﬂammation,
which is the foundation for many autoimmune diseases, including
lupus and rheumatoid arthritis. Once deposited either as anti-host
antibodies or as an immune complex, IgG activates innate immune
cells via FcγR. These are expressed as pro-inﬂammatory (FcγRI,
FcγRIIA/C,FcγRIIIA/B,FcγRIV)or anti-inﬂammatory (FcγRIIB)
receptors, some in a species-restricted manner, e.g., FcγRIV in
mice only, as discussed later. Macrophages, basophils, neutrophils,
and mast cells are activated by FcγR signals, often via FcγRIII,with
counter-regulation by FcγRIIB (Malbec and Daeron, 2007; Nim-
merjahn and Ravetch, 2008). Understanding signals emanating
from these receptors will offer new treatments for IgG-mediated
diseases. Here we review highlights of IgE signaling such as Lyn,
Fyn, and STAT5. We will also describe interplay with regulatory
cytokines IL-4, IL-10, and TGFβ1, and the potential signaling
overlap between IgE and IgG receptors in mast cells.
Src FAMILY KINASES ARE INTEGRAL TO IgE SIGNALING
Mast cell activation and IgE are almost synonymous topics that
have been studied in-depth. An early phase of degranulation and
eicosanoid secretion, and a late phase inﬂammatory cytokine pro-
duction, are both potently stimulated by multivalent interactions
between FcεRI-bound IgE molecules and antigen at the mast cell
surface. As a result, the crosslinking of these receptors into lipid
raft domains brings into proximity protein tyrosine kinases (PTK)
that may or may not be pre-associated with FcεRI. This makes for
a ripe setting of immunoreceptor tyrosine-based activation motif
(ITAM) trans-phosphorylation (Pribluda et al., 1994) and further
recruitment of other PTK, via Src homology 2 (SH2) domains,
that propagate the signal.
Crosslinking of FcεRI activates a variety of Src family kinases
(Eiseman and Bolen, 1992; Gilﬁllan and Rivera, 2009), this review
focuses on two wings of signaling that emerge from such an event.
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First, the stimulation of tyrosine kinase Syk through activity of
Lyn (a Src family kinase); Syk phosphorylates linker of activated T
cells (LAT) which in turn discharges its duty as a SH2-based scaf-
fold, eventually stimulating extracellular signal-regulated kinases
(ERK) and de novo transcription (Rivera and Gilﬁllan, 2006; Gil-
ﬁllan and Rivera, 2009). The second pathway involves the activity
of another Src family kinase, Fyn. Through the Grb2 associated
binding protein (Gab) 2, Fyn elicits signal transduction down the
canonical PI3K-Akt axis (Kim et al., 2008). Fyn is also essential
for early phase degranulation of mast cells through the transient
receptor potential channel 1 (TRPC1),a non-selective cation chan-
nel that is required for Ca2+ inﬂux, F-actin depolymerization, and
resultant release of packed granules (Suzuki et al., 2010).
Both Lyn and Fyn are positive mediators of FcεRI activity (Par-
ravicini et al., 2002;Gomez et al., 2005a;Rivera andGilﬁllan,2006).
However, a notable distinction exists in that Lyn also contributes
to the abatement of IgE-mediated signaling (Hernandez-Hansen
et al., 2004;Odomet al., 2004;Kalesnikoff andGalli, 2008). Beyond
its role in Syk recruitment, Lyn inﬂuences several inhibitory pro-
teins, including SHIP-1, SHP-2, DOK-1, and Cbp, leading to
decreased signaling in the PI-3 kinase and the Ras-MAPK cas-
cades (Satterthwaite et al., 1998; Takeshita et al., 1998; Hibbs et al.,
2002; Xu et al., 2005).
Lyn induces the activity of C-terminal Src kinase (Csk) by
directly phosphorylating the membrane-anchored Csk-binding
protein (Cbp;Odomet al., 2004;Kovarova et al., 2006), also known
as phosphoprotein associated with glycosphingolipid-enriched
microdomains (PAG). This event places Csk in close proxim-
ity to the FcεRI-associated Lyn and Fyn. Csk phosphorylates in
such a way to sterically hinder Src family kinase protein–protein
interactions (Gilﬁllan and Rivera, 2009). Two groups indepen-
dently uncovered Cbp/PAG as the essential factor potentiating Csk
localization at the plasmalemma (Brdicka et al., 2000; Kawabuchi
et al., 2000). Cbp is ubiquitously expressed and constitutively
tyrosine phosphorylated in some cell types; with a number of
SH2-mediated binding interactions occurring as a result of this
(Brdicka et al., 2000). Most notable is a positive interaction with
Csk upon phosphorylation of Cbp Y314 in rat (Takeuchi et al.,
2000) and Y317 in human (Brdicka et al., 2000). The functional
relationship between Src family kinases and Cbp was ﬁrst deﬁned
in T cells and, Raji and Jurkat cell lines. Csk and Cbp are pre-
associated in resting T-cells, however during T cell receptor (TCR)
aggregation Cbp is swiftly dephosphorylated, releasing Csk, result-
ing in the delocalization of the latter from the membrane (Brdicka
et al., 2000); thus the inhibitory phosphorylation on Lyn and Fyn
is lost. Interestingly the same study demonstrated an association
between Fyn and Cbp independent of an SH2 interaction (Brdicka
et al., 2000). Indeed in the setting of T cell activation, Fyn eventu-
ally rephosphorylates Cbp, reinstating theCsk elicited brake on Src
family kinase (Lindquist et al., 2003). However, in the context of
mast cells and FcεRI, Csk recruitment/activity through Cbp seems
to be more a function of post-aggregation Lyn activity (Honda
et al., 1997;Ohtake et al., 2002),with Lyn knockouts possessing un-
phosphorylated Cbp, therefore non-functional Csk (Odom et al.,
2004). Moreover, unlike resting T cells, Cbp is not constitutively
active in mast cells (Ohtake et al., 2002; Lindquist et al., 2003).
Importantly, genetic background has been shown to be key to
the negative responses associated with Lyn. It has been postulated
that this could be due to a Lyn:Fyn balance, e.g., C57BL/6 mice
express signiﬁcantly less Fyn than the 129/Sv strain. Lyn null
bone marrow-derived mast cells (BMMC) from the C57BL/6
strain have an impaired degranulation response to antigen, while
a similar knock-out (KO) in 129/Sv mast cells results in hyper-
degranulation. In contrast, Lyn deletion in either strain enhances
IgE-mediated cytokine production, revealing Lyn as a negative
regulator (Yamashita et al., 2007). As no similar negative roles
for Fyn have been observed in mast cells, one could hypothesize
that increased Fyn kinase, e.g., on the 129/Sv background, predis-
poses to FcεRI hyperactivity when the negative effects of Lyn are
absent. Yet other work has demonstrated that the function of Lyn
changes with the intensity of IgE-Antigen stimulus on mast cells
of similar background. Low intensity receptor activation induces
a positive signaling role for Lyn, leading to eventual activation of
Akt and p38, while high intensity activation of FcεRI elicits neg-
ative responses (Xiao et al., 2005). This bears resemblance to the
dual roles of Fyn in the context of TCR signaling.
STAT5 ACTIVITY IS MODULATED BY FcεRI IN A
FyN-DEPENDENT MANNER
The STAT family of transcription factors is best known as con-
taining the intermediaries of cytokine and growth factor signals.
Typically, aggregating cytokine receptor subunits with their asso-
ciated Janus (JAK) tyrosine kinases induce JAK auto- or trans-
phosphorylation and subsequent receptor phosphorylation, yield-
ing SH2 binding sites to which STATs dock. Generally, STATs are
then targeted by the JAK kinases, eliciting phosphotyrosine (pY)-
induced STAT dimers that shuttle into the nucleus and stimulate
target gene transcription (Schindler et al., 2007). In mast cells
one such process is the induction of STAT5 phosphorylation by
stem cell factor (SCF)/c-Kit, or IL-3, via JAK2 activation (Mui
et al., 1995; Ryan et al., 1997; Brizzi et al., 1999). One or both
of these cytokines are essential for the development and survival
of mast cells in vitro and in vivo. A series of work by our group
and others has established the critical part fulﬁlled by STAT5 in
mast cell development and survival. In particular, STAT5A appears
to be more important for survival as demonstrated by dominant
negative and gene KO approaches (Shelburne et al., 2003; Ikeda
et al., 2005). Bone marrow devoid of STAT5A has markedly higher
rates of apoptosis and lesser proliferation compared to wild type
when cultured in IL-3 or SCF alone. It should be noted, however,
in vitro mast cell development can be achieved by dual stimu-
lation with IL-3+ SCF (Shelburne et al., 2003). This could be
due to the overlap of STAT signaling, particularly from STAT3
(Sonnenblick et al., 2005) or STAT6 (Malaviya and Uckun, 2002).
In vivo, mast cells are present at birth, but cannot be detected
in total STAT5 KO mice by 12 weeks of age (Shelburne et al.,
2003; Barnstein et al., 2006; and our unpublished observations).
Later work demonstrated that STAT5 tyrosine phosphorylation
is induced by crosslinking FcεRI. STAT5 KO BMMC have an
attenuated yet functional early activation response, measured by
histamine and leukotriene B4 release, but a near complete inabil-
ity to induce cytokine production – the hallmark of the late phase
(Barnstein et al., 2006). Surprisingly, this defect is not the result
of poor cytokine mRNA induction. Instead, STAT5 appears to
inhibit mRNA-destabilizing factors as one mechanism to reg-
ulate mast cell cytokines. The expression of one such protein,
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tristetrapolin (TTP), is enhanced in STAT5 KO BMMC during
FcεRI crosslinkage; inhibiting TTP partially restored cytokine pro-
duction (Barnstein et al., 2006). The potential effects of STAT5
on other RNA binding factors such as HuR (human antigen R),
remains as yet unknown.
Until recently, the mechanism by which FcεRI stimulates phos-
photyrosine (pY)-STAT5 also remained unknown. Through EM
co-localization studies (similar to those in Wilson et al., 2007;
Xue et al., 2007; Andrews et al., 2008) clustering of STAT5 with
FcεRI upon antigen exposure has been observed. Our group has
found that Fyn is the indispensible kinase eliciting pY-STAT5
proximal to FcεRI in an IgE-dependent, IL-3/SCF-independent
manner (Pullen et al., 2012). STAT5 and Fyn were found to
co-immunoprecipitate in resting mast cells, an association that
dissipated with IgE-antigen stimulation. Surprisingly, knock out
of Gab2 – the scaffolding protein linking Fyn to PI3K signal-
ing – allowed a slight enhancement in IgE-mediated pY-STAT5.
Deﬁciency of SH2 tyrosine phosphatase (SHP) -1, a known Gab2
associate, replicates the Gab2 KO phenotype to a lesser extent
(Pullen et al., 2012). These data with other accumulating evi-
dence in non-mast cell studies (Yu et al., 2002; Kim et al., 2009),
which can also include SHP-2, paint a more complicated picture
of the role of Gab2. It is interesting to note that the latter work
(Kim et al., 2009) reports an interaction between Lyn and Gab2
that inhibits osteoclastogenesis. Furthermore, a direct association
between STAT3 and Gab2 has been reported (Ni et al., 2007),
warranting its examination in mast cells in consideration of sig-
nal overlap with STAT5. In our hands, Lyn suppression enhances
pY-STAT5 in a manner similar to Gab2 and SHP-1 loss. This is in
keepingwith the knownnegative effects of Lyn,where its deﬁciency
on a C57BL/6 background enhances STAT5 activation.
CYTOKINE REGULATION OF FcεRI SIGNALING
While Lyn and Fyn offer a means of ﬁne-tuning IgE signaling,
external regulation of the IgE receptor can be achieved through
cytokines, primarily TGFβ1, IL-10, and IL-4. TGFβ1 is a multipo-
tent cytokine regulating tissue repair, inﬂammation, proliferation,
migration, and angiogenesis (Kehrl et al., 1986; Yang et al., 2010a;
Yoshimura et al., 2010). It is linked to autoimmune diseases and
cancer (Letterio andRoberts, 1998; Blobe et al., 2000), and recently
shown to have a critical role in Treg and Th17 differentiation (Bet-
telli et al., 2006; Lee et al., 2009; Ziegler and Buckner, 2009).
Mast cells evoke TGFβ1-mediated paracrine signaling, by secreting
TGFβ1 as well as proteases that activate its latent form (Penning-
ton et al., 1992; Kanbe et al., 1999; Lindstedt et al., 2001). IL-10
belongs to a family of related cytokines including IL-19, IL-20,
IL-22, IL-24, and IL-26 (Kotenko, 2002). Cells involved in the
allergic response, including Th2 cells and mast cells, can produce
IL-10 (Moore et al., 1993, 2001). The well-documented ability
of IL-10 to inhibit macrophage activation and antigen present-
ing function suggests an important role in regulating the immune
response. This is clearly demonstrated in IL-10-deﬁcient mice,
which develop a severe autoimmune phenotype (Kuhn et al.,
1993), as IL-10-deﬁcient dendritic cells are highly potent activa-
tors of Th1 responses (He et al., 2005). The presence of IL-10
has been shown to regulate inﬂammatory responses to pathogen
infection (Gazzinelli et al., 1996; Hunter et al., 1997), protect from
endotoxic shock (Howard et al., 1993; Berg et al., 1995), and
control both acute and chronic inﬂammatory responses (Roers
et al., 2004). Clinically, IL-10 inhibits progression of rheumatoid
arthritis when delivered directly to the site of inﬂammation (Tra-
chsel et al., 2007). As such, IL-10 is being further studied as an
inﬂammatory therapeutic (Murray, 2006).
Our group and others have found that TGFβ1 and IL-10
suppress mast cell function and survival, offering homeostatic
feedback regulation (Bissonnette et al., 1997; Miller et al., 1999;
Gomez et al., 2005b; Norozian et al., 2006; Pemberton et al., 2006;
Wiener et al., 2007; Woodman et al., 2008). TGFβ1 inhibited IL-
3-dependent proliferation of mouse BMMC (Broide et al., 1989;
Toyota et al., 1995) and blocked their rescue from apoptosis by
SCF (Mekori and Metcalfe, 1994). Inhibitory effects of TGFβ1 on
mast cell function have also been shown. Bissonnette et al. (1997)
reported that antigen-induced histamine and TNF production
from rat peritoneal mast cells were inhibited by TGFβ1, whereas
Meade et al. (1992) showed that in vivo treatment with TGFβ1
blunted IgE-mediated,mast cell-dependent, immediate hypersen-
sitivity responses in mice. These effects could be partly due to
TGFβ1-mediated suppression of FcεRI expression (Gomez et al.,
2005b). Despite these studies supporting the theory that TGFβ1
inhibits mast cell function, contradicting evidence exists. This
includes a report by Kim and Lee (1999) that TGFβ1 potentiates
IgE-dependent cutaneous anaphylaxis in rats. Like TGFβ1, IL-10
can inhibit FcεRI expression and IgE-mediated cytokine produc-
tion in mast cells (Marshall et al., 1996; Lin and Befus, 1997; Royer
et al., 2001a,b; Gillespie et al., 2004). Our recent work showed
that IL-10 is produced endogenously during mast cell develop-
ment, and suppresses mast cell numbers and FcεRI expression
(Speiran et al., 2009). Exogenous IL-10 can inhibit the differentia-
tion and survival of immaturemousemast cells, eliciting apoptosis
via reduction of c-Kit signaling, caspase activation, and damage to
the mitochondria (Bailey et al., 2006; Speiran et al., 2009).
Wehave investigated themeans bywhich IL-10 andTGFβ1 sup-
press mast cell activation. In recent work, we found that adding
exogenous IL-10 or TGFβ1 to mast cells leads to a gradual decline
in Fyn and STAT5 protein levels, reaching its nadir in 3–4 days
(Kennedy Norton et al., 2008 and data not yet published). This
slow onset could be argued to allow protective mast cell func-
tions prior to reinstating immune homeostasis. By targeting the
Fyn-STAT5 pathway, these cytokines effectively disrupt mast cell
cytokine production and survival. Our most recent ﬁndings show
that a set of microRNAs (miRs) is regulated by IL-10 and TGFβ1;
miRs that could target Fyn and STAT5, based on in silico analyses.
We look forward to unraveling this area, in hopes of providing
clues to molecular therapies targeting mast cells.
IL-4 is a pleiotropic cytokine that participates in driving the
polarization of T cells toward a Th2 phenotype by inhibiting IFN-
γ production and inducing further production of IL-4 by T cells
(Foster et al., 2002; Galli et al., 2008). IL-4 signals by binding to
the IL-4Rα chain, present as a heterodimer, paired with either the
common gamma chain or the IL-13Rα1, creating the type I and
type II receptors, respectively. IL-4 plays an important role in the
development of asthma by supporting the early development of
Th2 cells and promoting B cell isotype switching to IgE. Along
with IL-13, IL-4 contributes to the pathophysiology of asthma
www.frontiersin.org May 2012 | Volume 3 | Article 117 | 3
Pullen et al. Fyn/Stat5 Signaling in Mast Cells
by inducing bronchial hyperresponsiveness and goblet cell mucus
production (Wills-Karp and Finkelman, 2008). Like IL-10, IL-4
can be secreted by mast cells (Brown and Haniﬁn, 1989), and
is produced constitutively in cultures of developing mast cells
(Speiran et al., 2009). The combination of exogenous IL-4 and IL-
10 can inhibitmast cell differentiation and survival (Yeatman et al.,
2000; Bailey et al., 2004; Bouton et al., 2004) through mechanisms
not used independently by either cytokine. Moreover, deletion of
IL-4 [or IL-10] enhanced BMMC growth and FcεRI expression
(Speiran et al., 2009). Also similar to IL-10 and TGFβ1, IL-4 acts
on mature mouse mast cells to decrease FcεRI expression and sig-
naling through a STAT6 dependent pathway (Ryan et al., 1998).
However, IL-4 has been repeatedly shown to have an enhancing
effect on human FcεRI expression (Toru et al., 1996; Bischoff et al.,
1999; Lorentz and Bischoff, 2001; Macey et al., 2010). For this rea-
son, IL-4 and its receptor have been attractive candidates for the
treatment of asthma. Unfortunately, therapies targeting IL-4 have
not yielded promising results due to possible redundancy from
IL-13 through the type II receptor. Currently in clinical trials is
a monoclonal antibody targeting IL-4Rα, an antisense oligonu-
cleotide that prevents translation of the IL-4Rα chain, and an
IL-4 mutein that interferes with the binding of endogenous IL-4
(Nguyen and Casale, 2011).
We recently found interplay between IL-4 andTGFβ1 that could
contribute to immune homeostasis. TGFβ1 antagonizes IL-4 sig-
naling in mast cells, by down-regulating IL-4 receptor expression
and suppressing STAT6 activation (Macey et al., 2010). TGFβ1 has
also been shown to prevent IL-4 expression, by inducing the adap-
tor protein Nedd4 family-interacting protein 1 (Ndﬁp1) in Treg.
Ndﬁp1 participates in the ubiquitination of the Jun family tran-
scription factors needed for IL-4 transcription (Beal et al., 2011).
Interestingly, IL-4 demonstrates similar antagonism of TGFβ1.We
found that IL-4 suppresses TGFβ receptor expression and signal-
ing in mast cells, showing these two cytokines are able to ﬁne tune
mast cell responses (Macey et al., 2010).
IgG-MEDIATED MAST CELL ACTIVITY
As discussed earlier, mast cell activation can be achieved through
a variety of stimuli, ranging from cytokines to allergen-speciﬁc
immunoglobulins. In allergic and inﬂammatory pathologies,
allergen-speciﬁc IgE crosslinks mast cell FcεRI and triggers the
activation of intracellular signaling molecules, ultimately resulting
in mediator release and chemotaxis. However in addition to FcεRI,
mast cells express the IgG receptor family (FcγR). Of the high-
afﬁnity IgG receptors, both humans and mice possess FcγRI,while
FcγRIV is restricted to mice. The low afﬁnity FcγRII and FcγRIII,
are found in humans andmice.However, there are three FcγRII (A,
B, andC) and twoFcγRIII (A andB) in humans,whereasmice have
one receptor of each type (FcγRIIB and FcγRIIIA; Nimmerjahn
and Ravetch, 2008). Further complicating receptor distribution
among species is evidence that receptor type expression is also vari-
able according tomast cell phenotype (Benhamouet al., 1990), e.g.,
peritoneal vs. BMMC, along with the proﬁle of mediator release
(Katz et al., 1992), e.g., leukotriene C4 vs. prostaglandin D2.
Activating FcγR on mouse cells consist of a ligand-binding
alpha-chain (α) and a signal-transducing gamma-chain (γ)
bearing ITAMs, which once phosphorylated upon receptor
crosslinking, act as docking sites for signaling molecules such as
Syk kinase; this results in the activation of signaling pathways.
In contrast, ligand binding can also result in downregulation of
antigen-dependent mediator release due to the existence of the
immunoreceptor tyrosine-based inhibitory motifs (ITIMs) on the
cytosolic portion of the FcγRIIB α-chain. Phosphorylation of
ITIMs upon FcγRIIB ligation induces the activation of Lyn kinase,
which can recruit and activate phosphatases like SHIP in addi-
tion to directly acting upon ITIMs, leading to decreased mediator
release (Fong et al., 1996;Ono et al., 1996). FcγRIIB inhibits several
aspects of mast cell and basophil functions such as IgE-dependent
degranulation and IL-4 production (Daëron et al., 1993, 1995).
In addition to mast cells, FcγRIIB is expressed by other immune
cells including dendritic cells,macrophages, activated neutrophils,
basophils, and B cells. When expressed by these cells, FcγRIIB
inhibits the functions of activating FcγRs, e.g., phagocytosis and
pro-inﬂammatory cytokine release (Daëron et al., 1993, 1995;
Nimmerjahn and Ravetch, 2008).
Fcγ receptors share the common gamma subunit with FcεRI,
and not surprisingly, similar signaling pathways (Kurosaki et al.,
1992; Dombrowicz et al., 1997). Although the importance of Syk
kinase in IgG signaling has been demonstrated (Crowley et al.,
1997; Lach-Triﬁlieff et al., 2000) little is known about Src family
kinase functions in FcγR-mediated mast cell activation. Our lat-
est data demonstrates FcγR-induced mast cell activation of Fyn
and Lyn kinases, and downstream initiation of the PI3K-Akt,
Erk, p38, and JNK pathways (Falanga et al., 2012). In the same
report, it was revealed that Fyn and Lyn kinases have opposing
roles upon FcγR crosslinking, since Fyn-deﬁcient (KO) mast cells
displayed decreased degranulation and mediator release, whereas
an exacerbated response was observed with Lyn KO mast cells.
This demonstrates that FcγR-induced mast cell mediator release
is regulated in a Fyn- and Lyn-dependent manner.
In pathologic and extremely rare conditions, mast cell activa-
tion with antigen-speciﬁc IgE can lead to anaphylaxis, a rapid, and
life-threatening hypersensitivity reaction. Historically, the onset
and regulation of anaphylaxis was exclusively attributed to the
generally known classical pathway of anaphylaxis involving IgE-
mediated FcεRI mast cell activation and subsequent histamine
release (Miyajima et al., 1997;Galli et al., 2005).However, elegantly
conducted research on murine models demonstrated that an ana-
phylactic reaction can be induced through an IgG-FcγR pathway
(Strait et al., 2002; Obata et al., 2007; Tsujimura et al., 2008;
Jonsson et al., 2011a). In this alternative pathway, activation of
basophils and macrophages (FcγRI and FcγRIII; Strait et al., 2002;
Obata et al., 2007; Tsujimura et al., 2008), and recently FcγRIV on
neutrophils (Jonsson et al., 2011a) elicits anaphylactic symptoms,
including a drop in core body temperature. Although mast cell
contribution in IgG-mediated anaphylaxis was insigniﬁcant – as
mast cell-deﬁcient mice still developed IgG-induced anaphylaxis
via platelet activating factor (PAF) – recent data demonstrate
that mast cells account for the majority of circulating hista-
mine during FcγR-induced passive systemic anaphylaxis (PSA),
which is regulated by Fyn and Lyn (Falanga et al., 2012). Addi-
tionally, mast cells have recently been reported to be responsible
for FcγRIIA-dependent cutaneous anaphylaxis whereas mono-
cytes/macrophages and neutrophils were found to be involved in
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FIGURE 1 | Overlap in FcεRI, FcγRIII, and FcγRIIB signaling. IgE-bound
multivalent antigen or IgG immune complexes induce FcεRI or
FcγRIII/FcγRIIB crosslinking, respectively. These events lead to the swift
activation of Src family kinases Lyn and Fyn. Both positively inﬂuence
downstream signaling through Syk and LAT, but Lyn also produces
negative feedback by phosphorylating ITIMs and by inducing the Csk
recruitment via SH2 interactions with phosphorylated Cbp/PAG.
Additionally, Fyn stimulates the PI3-K axis. Under FcεRI-driven signaling,
Fyn activates STAT5, transcription factors that are required for mast cell
survival (STAT5A) and cytokine production (STAT5B). Regulatory cytokines
such as IL-10 andTGFβ1 can inhibit Fyn and STAT5 production, possibly
through the induction of speciﬁc miRs.
FcγRIIA-dependent systemic anaphylaxis (Jonsson et al., 2011b).
Taken together, these ﬁndings bring new insights to the function
of Fyn and Lyn kinases downstream of FcγR stimulation and the
role of mast cells in IgG-mediated pathologies.
CLOSING REMARKS
Exploration of the biological chemistry behind IgG signaling will
be an important activity contributing to efforts in understand-
ing IgG-mediated hypersensitivity disorders. Lessons from FcεRI
studies serve as a valuable model offering clues in this pursuit.
We posit that the Fyn/STAT5 pathway will be an important reg-
ulator in IgG-mediated mast cell pathology, and here we have
reviewed key areas of IgE-mediated signaling where IgG cues are
likely to intersect, summarized by Figure 1. The similarities also
offer attractive lines of study with respect to the interplay of IgG
and other exogenous signals such as IL-4, IL-10, and TGFβ1,which
canhave their own effects onFyn andSTAT5.Notwithstanding this
potential, there are still many avenues of investigation that need
attention.
First is the need for a more precise dissection of STAT5 acti-
vation and mobilization as an effect of IgE and IgG receptor
crosslinking. STAT5 is actually represented by two similar but
distinct proteins: STAT5A and STAT5B (Grimley et al., 1999).
As mentioned earlier STAT5A is important for the development
and proliferation of mast cells (Shelburne et al., 2003), whereas
STAT5Bhas been identiﬁed as the regulator of cytokineproduction
(Pullen et al., 2012). Thus far these roles do not appear inter-
changeable, e.g., STAT5A depletion does not signiﬁcantly affect
IgE-mediated cytokine production. While the role of STAT5B in
mast cell development has not beendirectly addressed, its impact is
likely redundant since total STAT5KObonemarrow can be rescued
by reconstituting STAT5A (Shelburne et al., 2003). One question
needing pursuit asks if there is a speciﬁcity for which STAT5 iso-
form associates with Fyn and FcεRI. Furthermore, which STAT5
mobilizes to the nucleus when, and what are their targets? Com-
plicating this matter is the fact that in addition to tyrosine at least
two serines are phosphorylated, and the function of each phos-
phorylated residue could possibly diverge between each STAT5.
For example, phosphorylation of STAT5A serines 725 and 779 has
been identiﬁed as a requirement for leukemogenic transformation
(Friedbichler et al., 2010), and there are slight primary sequence
variations in the location of the known target serines and tyrosine
between STAT5A and STAT5B.
Second is the need to further dissect the roles of other Fc recep-
tor signal mediators. For example, double KO of the Tec kinases
Itk and Btk was found to inhibit degranulation/histamine release
and impaired mast cell granularity (Iyer et al., 2011). Interestingly,
in the same work c-Kit expression and mast cell development
www.frontiersin.org May 2012 | Volume 3 | Article 117 | 5
Pullen et al. Fyn/Stat5 Signaling in Mast Cells
were not affected, however the double KOs showed enhanced
proliferation. Furthermore, FcεRI and the FcγR share common γ-
chains containing ITAMs that, when phosphorylated, can recruit
Syk (Crowley et al., 1997; Lach-Triﬁlieff et al., 2000; Nimmer-
jahn and Ravetch, 2008). In FcεRI signaling, the activation of Syk
through Lyn is a well-known effector of mast cell function; if this
happens in the context of FcγR crosslinking is open for investiga-
tion. The association of Lyn [and Fyn] with FcεRI is an enigmatic
matter, as it is known to be dynamic and possibly compartmen-
talized (Gilﬁllan and Rivera, 2009). This in combination with the
diversity of IgG receptors onmast cells suggests that,while the high
afﬁnity IgE receptor serves as a good model, there is much more to
these signaling stories than is currently understood. For example,
additional exploration of FcγR expression proﬁles in mast cells of
different sources, phenotypes, and species will be important for
interpreting data.
Finally, unraveling these discrete biochemical questions should
be matched with in vivo studies of STAT5 functions in allergic and
autoimmune diseases, especially those in which mast cells are a key
component. Therapies targeting mast cell activation and secreted
mediators have proven effective in allergic disease. If the Fyn-Stat5
pathway operates as a key signaling pathway as we hypothesize,
selective targeting of this axis could prove therapeutic to many
disorders. These clinical goals are critical, and should come as
a natural product of efforts to understand the fundamentals of
immune homeostasis.
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